journal article·2023-07Open access

Impact of Fibrinogen, Fibrin Thrombi, and Thrombin on Cancer Cell Extravasation Using In Vitro Microvascular Networks

Emmanouil Angelidakis, Sophia Chen, Shun Zhang, Zhengpeng Wan, Roger D. Kamm, Sarah E. Shelton

Advanced Healthcare Materials· Volume 12· Issue 19

Abstract

Abstract A bidirectional association exists between metastatic dissemination and the hypercoagulable state associated with many types of cancer. As such, clinical studies have provided evidence that markers associated with elevated levels of coagulation and fibrinolysis correlate with decreased patient survival. However, elucidating the mechanisms underpinning the effects of different components of the coagulation system on metastasis formation is challenging both in animal models and 2D models lacking the complex cellular interactions necessary to model both thrombosis and metastasis. Here, an in vitro, 3D, microvascular model for observing the formation of fibrin thrombi is described, which is in turn used to study how different aspects of the hypercoagulable state associated with cancer affect the endothelium. Using this platform, cancer cells expressing ICAM‐1 are shown to form a fibrinogen‐dependent bridge and transmigrate through the endothelium more effectively. Cancer cells are also demonstrated to interact with fibrin thrombi, using them to adhere, spread, and enhance their extravasation efficiency. Finally, thrombin is also shown to enhance cancer cell extravasation. This system presents a physiologically relevant model of fibrin clot formation in the human microvasculature, enabling in‐depth investigation of the cellular interactions between cancer cells and the coagulation system affecting cancer cell extravasation.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Blood properties and coagulation · Platelet Disorders and Treatments · Inflammatory Biomarkers in Disease Prognosis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biological Engineering Massachusetts Institute of Technology Cambridge MA 02139 USA

Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge MA 02139 USA

Department of Medical Oncology Dana Farber Cancer Institute Boston MA 02215 USA

Funding

Norges Idrettshøgskole

References (100+)

Show source-provided references
1. 10.1111/j.1538-7836.2007.02374.x10.1111/j.1538-7836.2007.02374.x ↗
2. Razak N. B. A. · Cancers · 2018 · 10 · 1
3. 10.1038/sj.bjc.660588310.1038/sj.bjc.6605883 ↗
4. 10.1055/s-0037-161613910.1055/s-0037-1616139 ↗
5. 10.1093/ajcp/88.5.59610.1093/ajcp/88.5.596 ↗
6. 10.3324/haematol.2011.05471810.3324/haematol.2011.054718 ↗
7. 10.1152/physrev.00016.201110.1152/physrev.00016.2011 ↗
8. 10.1182/blood-2010-08-30030110.1182/blood-2010-08-300301 ↗
9. 10.1038/s41467-016-0009-610.1038/s41467-016-0009-6 ↗
10. 10.1182/blood.V88.1.146.14610.1182/blood.V88.1.146.146 ↗
11. 10.1182/blood.V95.4.1158.004k31_1158_116610.1182/blood.V95.4.1158.004k31_1158_1166 ↗
12. 10.4137/CMO.S1899110.4137/CMO.S18991 ↗
13. 10.1016/j.cell.2011.02.01310.1016/j.cell.2011.02.013 ↗
14. 10.1182/blood.V96.10.330210.1182/blood.V96.10.3302 ↗
15. 10.1182/blood-2004-02-043410.1182/blood-2004-02-0434 ↗
16. 10.1182/blood-2007-01-06599510.1182/blood-2007-01-065995 ↗
17. 10.1073/pnas.120124010910.1073/pnas.1201240109 ↗
18. 10.1039/C6LC00380J10.1039/C6LC00380J ↗
19. 10.1038/s41467-018-02990-x10.1038/s41467-018-02990-x ↗
20. 10.1016/S0002-9440(10)65628-310.1016/S0002-9440(10)65628-3 ↗
21. 10.1038/nrc109810.1038/nrc1098 ↗
22. 10.1038/nprot.2017.01810.1038/nprot.2017.018 ↗
23. 10.4103/0019-5049.14464310.4103/0019-5049.144643 ↗
24. Bain B. J. · 2015
25. 10.1182/blood-2013-08-52386010.1182/blood-2013-08-523860 ↗
26. 10.1083/jcb.20120803010.1083/jcb.201208030 ↗
27. 10.1083/jcb.20160802510.1083/jcb.201608025 ↗
28. S.Chen T.Markovich F. C.MacKintosh 2022 http://arxiv.org/abs/2204.00222.
29. 10.1016/j.matbio.2016.08.00310.1016/j.matbio.2016.08.003 ↗
30. 10.1002/jbm.a.3703310.1002/jbm.a.37033 ↗
31. 10.1055/s-0037-161303010.1055/s-0037-1613030 ↗
32. 10.1007/s10735-010-9298-y10.1007/s10735-010-9298-y ↗
33. 10.1006/jmcc.2000.117910.1006/jmcc.2000.1179 ↗
34. 10.1167/iovs.16-1942010.1167/iovs.16-19420 ↗
35. 10.1002/adfm.20220676710.1002/adfm.202206767 ↗
36. 10.1016/j.biomaterials.2019.05.02210.1016/j.biomaterials.2019.05.022 ↗
37. 10.1074/jbc.273.46.3071910.1074/jbc.273.46.30719 ↗
38. 10.1002/ijc.2434010.1002/ijc.24340 ↗
39. 10.1161/01.ATV.16.3.48810.1161/01.ATV.16.3.488 ↗
40. 10.1002/rth2.1219110.1002/rth2.12191 ↗
41. 10.1038/bjc.2014.9010.1038/bjc.2014.90 ↗
42. 10.1093/jjco/28.12.74010.1093/jjco/28.12.740 ↗
43. Kozłowski L. · Rocz. Akad. Med. Białymstoku · 2003 · 48 · 82
44. 10.1016/0014-5793(89)80476-410.1016/0014-5793(89)80476-4 ↗
45. 10.1111/j.1538-7836.2007.02808.x10.1111/j.1538-7836.2007.02808.x ↗
46. 10.1097/MD.000000000000669410.1097/MD.0000000000006694 ↗
47. 10.1186/s12885-015-2026-y10.1186/s12885-015-2026-y ↗
48. Zhang Y. · Clinics · 2020 · 75 · 1
49. 10.1038/ncomms1403510.1038/ncomms14035 ↗
50. 10.1073/pnas.140855611110.1073/pnas.1408556111 ↗
51. 10.1152/ajpheart.00400.200810.1152/ajpheart.00400.2008 ↗
52. 10.4049/jimmunol.163.2.66810.4049/jimmunol.163.2.668 ↗
53. 10.1053/j.gastro.2004.09.01110.1053/j.gastro.2004.09.011 ↗
54. Dai H. · Biomed. Rep. · 2018 · 9 · 453
55. 10.1158/0008-5472.CAN-09-331210.1158/0008-5472.CAN-09-3312 ↗
56. 10.1158/0008-5472.CAN-13-060210.1158/0008-5472.CAN-13-0602 ↗
57. 10.3390/cells910226910.3390/cells9102269 ↗
58. 10.7150/thno.5363710.7150/thno.53637 ↗
59. 10.1039/c3ib40149a10.1039/c3ib40149a ↗
60. 10.4049/jimmunol.158.4.188010.4049/jimmunol.158.4.1880 ↗
61. 10.1161/01.ATV.20.3.65210.1161/01.ATV.20.3.652 ↗
62. 10.1023/A:101398591175910.1023/A:1013985911759 ↗
63. 10.1038/nrneph.2015.17710.1038/nrneph.2015.177 ↗
64. 10.1111/j.1538-7933.2003.00617.x10.1111/j.1538-7933.2003.00617.x ↗
65. 10.1016/S0049-3848(99)00169-310.1016/S0049-3848(99)00169-3 ↗
66. 10.1038/sj.bjc.669006310.1038/sj.bjc.6690063 ↗
67. Yang E. · Oncogene · 2015 · 1 · 1529
68. 10.1051/ject/20053739010.1051/ject/200537390 ↗
69. 10.1016/j.yexcr.2006.09.00810.1016/j.yexcr.2006.09.008 ↗
70. 10.1007/s00418-011-0804-410.1007/s00418-011-0804-4 ↗
71. 10.18632/oncotarget.2101510.18632/oncotarget.21015 ↗
72. 10.1002/jcp.2406110.1002/jcp.24061 ↗
73. 10.1126/sciadv.abg813910.1126/sciadv.abg8139 ↗
74. 10.1002/jcb.2122010.1002/jcb.21220 ↗
75. 10.1038/s41598-020-79139-810.1038/s41598-020-79139-8 ↗
76. 10.1021/bi900487d10.1021/bi900487d ↗
77. 10.1371/journal.pone.000539110.1371/journal.pone.0005391 ↗
78. 10.1055/s-0039-169500810.1055/s-0039-1695008 ↗
79. 10.1038/nm119810.1038/nm1198 ↗
80. 10.1158/0008-5472.CAN-15-132510.1158/0008-5472.CAN-15-1325 ↗
81. 10.1158/1078-0432.CCR-06-139310.1158/1078-0432.CCR-06-1393 ↗
82. 10.1002/jso.1005310.1002/jso.10053 ↗
83. 10.1046/j.1365-2559.2000.00933.x10.1046/j.1365-2559.2000.00933.x ↗
84. 10.1093/carcin/bgh21110.1093/carcin/bgh211 ↗
85. 10.1055/s-0037-161341210.1055/s-0037-1613412 ↗
86. 10.1007/s00535-017-1329-y10.1007/s00535-017-1329-y ↗
87. 10.1158/0008-5472.CAN-11-143210.1158/0008-5472.CAN-11-1432 ↗
88. 10.1016/0092-8674(89)90946-X10.1016/0092-8674(89)90946-X ↗
89. 10.1074/jbc.272.8.536010.1074/jbc.272.8.5360 ↗
90. 10.1186/bcr139810.1186/bcr1398 ↗
91. 10.1007/s11373-004-8170-z10.1007/s11373-004-8170-z ↗
92. 10.1186/s12885-017-3823-210.1186/s12885-017-3823-2 ↗
93. 10.1074/jbc.271.39.2427010.1074/jbc.271.39.24270 ↗
94. 10.4049/jimmunol.165.9.525510.4049/jimmunol.165.9.5255 ↗
95. 10.1038/bjc.2012.17710.1038/bjc.2012.177 ↗
96. 10.18632/oncotarget.1941710.18632/oncotarget.19417 ↗
97. 10.1158/1535-7163.MCT-12-052910.1158/1535-7163.MCT-12-0529 ↗
98. 10.1182/blood.V90.9.359510.1182/blood.V90.9.3595 ↗
99. Lickert S. · Sci. Adv. · 2022 · 8331 · 1
100. 10.1016/j.ccr.2011.09.00910.1016/j.ccr.2011.09.009 ↗